
Characterizing an Ampa Receptor Splice Modulator in Preventing EpileptogenesisAward last edited on: 4/11/16
Sponsored Program
SBIRAwarding Agency
NIH : NINDSTotal Award Amount
$494,735Award Phase
2Solicitation Topic Code
-----Principal Investigator
Melanie K TallentCompany Information
Lifesplice Pharma LLC
1 Great Valley Parkway Suite 20
Malvern, PA 19355
Malvern, PA 19355
(610) 296-5401 |
info@lifesplicepharma.com |
www.lifesplicepharma.com |
Location: Single
Congr. District: 06
County: Chester
Congr. District: 06
County: Chester
Phase I
Contract Number: 1R43NS076135-01Start Date: 9/1/11 Completed: 8/31/13
Phase I year
2011Phase I Amount
$333,829Public Health Relevance:
In spite of the recent large increase in the number of drugs available to treat epilepsy, there are no drugs in clinical use that prevent the development of this disease in vulnerable populations. We have developed a novel compound that acts at the level of gene transcription to normalize excitability in the epileptic brain and prevents changes in the brain associated with the development of epilepsy. Our proposed research is designed to validate this compound as a drug for preventing epilepsy in both infants and adults.
Thesaurus Terms:
2(3h)-Furanone, 3-Ethyldihydro-4-((1-Methyl-1h-Imidazol-5-Yl)Methyl)-, (3s-Cis)-;21+ Years Old;Ampa Receptors;Adult;Adult Human;Alternate Splicing;Alternative Rna Splicing;Alternative Splicing;Ammon Horn;Animal Disease Models;Animal Model;Animal Models And Related Studies;Anti-Sense Oligonucleotides;Antisense Agent;Antisense Oligonucleotides;Aran-Duchenne Disease;Bilateral;Body Tissues;Brain;Brain Nervous System;Brain Trauma;Chemistry;Chronic;Clinical;Clinical Trials;Cognition;Cognitive;Cognitive Deficits;Comorbidity;Cornu Ammonis;Cruveilhier Disease;Development;Disease;Disorder;Dose;Drugs;Encephalon;Epilepsy;Epileptic Seizures;Epileptics;Epileptogenesis;Gene Expression Inhibitor;Gene Targeting;Gene Transcription;Generalized Status Epilepticus;Genetic Transcription;Glutamate Receptor;Glutamates;Goals;Hippocampus;Hippocampus (Brain);Hour;Human;Infant;Injection Of Therapeutic Agent;Injections;Isoforms;Kinetics;L-Glutamate;Loinc Axis 2 Property;Man (Taxonomy);Marketing;Mediating;Medication;Mice;Mice Mammals;Modeling;Modern Man;Monitor;Motor;Murine;Mus;Muscular Dystrophies;Myodystrophica;Myodystrophy;Neonatal;Nerve Impulse Transmission;Nerve Transmission;Nervous System Diseases;Neurologic Disorders;Neurological Disorders;Neuronal Transmission;Oligo;Oligonucleotides;Pharmaceutic Preparations;Pharmaceutical Preparations;Pilocarpine;Predisposition;Property;Protein Isoforms;Pyramidal Neuron;Rna Expression;Rna Splicing;Reporting;Research;Seizure Disorder;Seizures;Small Interfering Rna;Specificity;Spinal Muscular Atrophy;Splicing;Status Epilepticus;Susceptibility;Synapses;Synaptic;Technology;Testing;Therapeutic;Time;Tissues;Transcript;Transcription;Traumatic Brain Injury;Traumatic Encephalopathy;Variant;Variation;Vulnerable Populations;Adult Human (21+);Adulthood;Behavior Test;Behavioral Test;Brain Tissue;Chronic Pain;Chronic Painful Condition;Clinical Investigation;Co-Morbidity;Cognitive Function;Design;Designing;Developmental;Disease/Disorder;Drug/Agent;Epilepsia;Epileptiform;Epileptogenic;Excitotoxicity;Glutamatergic;Hippocampal;Hippocampal Pyramidal Neuron;In Vivo;Kainate;Model Organism;Mouse Model;Muscle Dystrophy;Neonate;Nervous System Disorder;Neurological Disease;Neurotransmission;New Approaches;New Therapeutics;Next Generation Therapeutics;Novel;Novel Approaches;Novel Strategies;Novel Strategy;Novel Therapeutics;Prevent;Preventing;Protective Effect;Receptor Expression;Sirna;Synapse;Traumatic Brain Damage;Vulnerable Group
Phase II
Contract Number: 5R43NS076135-02Start Date: 9/1/11 Completed: 8/31/13